Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa, Open-label, Single-arm, Two Stage, Multi-centre Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Repeated Subcutaneous Administration of BIM23B065 in Subjects With Acromegaly

NCT03045302 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT03045302
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03045302 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa, Open-label, Single-arm, Two Stage, Multi-centre Study to Investigate the Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of Repeated Subcutaneous Administration of BIM23B065 in Subjects With Acromegaly
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Terminated
Start date
January 26, 2017
Completion date
June 2, 2017
Enrollment
4 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acromegaly